/
We are a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of unique RNA-targeted therapeutics, siRNA knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. Applying our proprietary, differentiated and innovative technologies, and through collaborations with our strategic partners,…
$16.94
$0.29 (-1.66%)
Live · 07:56 PM
The business is unprofitable at the operating level (-31.83% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 15.6%, still solid. Margins contracted 43.3pp, which offsets some of the top-line progress.
At 48x earnings, the current multiple leaves limited room for execution misses or growth deceleration. ROIC dropped from 7.36% to -21.89%, capital efficiency is deteriorating.
48.4x earnings, 18.0x FCF. The market is pricing in years of above-average growth. If that thesis breaks, downside from multiple compression alone could be 30%+. This is a stock where you're paying for the future, not the present.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$2.18B
▲ +15.6% YoY
Net Income (TTM)
-$64M
▼ -403.3% YoY
Op. Margin
-1.88%
▼ -43.3pp YoY
ROIC
-1.65%
▼ -29.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$115M
▲ +10.3% YoY
Op. Cash Flow (TTM)
$175M
▲ +0.1% YoY
Net Debt
$383M
Cash & Equiv.
$653M
5Y CAGR: +32.4%
Continue Research
At a P/E of 48.4 and a price-to-free-cash-flow of 18.0, Sarepta Therapeutics (SRPT) trades around a two-stage DCF intrinsic value of about $20.32 per share, so at $16.94 the stock looks around fair value (20.0% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Sarepta Therapeutics scores 57/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $20.32 per share for SRPT, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $15.24. At today's $16.94, that puts the stock about 20.0% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Sarepta Therapeutics scores 57 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a -1.9% operating margin and a -1.7% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. SRPT currently trades around its estimated intrinsic value and scores 57/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.